We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.295 | 2.21 | 2.28 | - | 204,575 | 10:04:44 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.81M | -0.0114 | -2.01 | 7.63M |
Date | Subject | Author | Discuss |
---|---|---|---|
24/1/2018 07:24 | Waterloo, Ham, agreed, this was a smart move in my opinion. | sharedgain | |
24/1/2018 07:24 | Big boots completely disagree on the basis if they are as confident as they Make out then why would you sell at 144 when in a month you could raise at a much higher price ask yourself that question | best1467 | |
24/1/2018 07:22 | Best Until we know the phase three results all bets are off. I do not believe Tim knew the results when he gave those interviews. | njb67 | |
24/1/2018 07:21 | You can make a "case" either way I reckon on this, but on balance if I were management and approached to get stock why wouldn't you? The pricing however leaves a little to be desired and should have been nearer the monthly average at or over £1.50....not too far off but they could have been harder on pricing.... | qs99 | |
24/1/2018 07:20 | I agree Njb67, Its a positive move! | flavio_monteiro | |
24/1/2018 07:20 | BEST, The City needs institutions with deep pockets to support their growth, this comes at a price The news today is fantastic and puts IMM on a sound footing | bigboots | |
24/1/2018 07:19 | Minimal dilution . Good to get it out of the way . Sensible move . | talkman2 | |
24/1/2018 07:18 | Ham Indeed. This reduces the short term financial risk. It is an insurance policy against disappointments phase 3 results. I see this as a positive move. GLA | njb67 | |
24/1/2018 07:18 | Been in this for 5 years.find this placing an absolute disgrace Leads me to question the potential of lupuzor why would you sell shares at 144 a month before ,if we are led to believe as that snake T MCArthy tells us we have a multi billion drug it just doesn't make any sense why should institutions get the gift of getting in at 144 at this stage shows how much they appreciate there long time retail investors disgrace. | best1467 | |
24/1/2018 07:16 | Looks like my pal was right | toolsmoker | |
24/1/2018 07:15 | Fair play to those that knew and were adamant, can't remember which posters! Anyway, instis wouldn't stump up £10m if they were not confident IMO so actually takes away a decent chunk of immediate finance "risk" so fair play why wouldn't you.....GLA | qs99 | |
24/1/2018 07:12 | Dafad..yes I know VRS could be a huge one, I have them parked in the ISA | ny boy | |
24/1/2018 07:11 | Impressed that some knew yesterday. Well as someone said yesterday, better raise £10m by diluting 5% than trying to raise the same amount with a 30% ditution if results were not ideal. Positive is that ii's are prepared to put money on the table now at this price. | hamhamham1 | |
24/1/2018 07:10 | Well I stand corrected about the placing but due to institutional demand that is encouraging.. I hope I can get some more this morning, certainly draws a line of support for the share price now. GLA, looks like exciting times ahead if institutions want in! | ny boy | |
24/1/2018 07:09 | Sensible and prudent IMO. Raise when you don't need it and the 'sun is shining'. | waterloo01 | |
24/1/2018 07:08 | Well that's out of the way it's onwards and upwards,vrs did a placing at 18pb6 weeks ago-share price is now 96p,placings are not always bad | dafad | |
24/1/2018 07:05 | Ouuuucccchhhhhhh A big tanking on the cards for this one!!!! | pjj71 | |
24/1/2018 07:03 | 24 JANUARY 2018 ImmuPharma PLC ("ImmuPharma" or the "Company") SUCCESSFUL PLACING TO RAISE £10 MILLION ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that, in response to institutional demand, it has completed a fundraise totalling £10 million (before expenses) via a placing of 6,944,445 new ordinary shares of 10p each in the Company ("Ordinary Shares") at a price of 144p per share (the "Placing Shares") with new and existing investors (the "Placing"). Key highlights: £10 million (before expenses) raised for the Company via the issue of Placing Shares: · Major new and existing institutional investors have participated in the Placing; and · ImmuPharma will apply these additional funds to support future investment in ImmuPharma's P140 peptide platform. The proceeds of the Placing will also provide the Company with additional working capital. Commenting on the announcement, Tim McCarthy, Chairman, said: "With our recent key milestone being announced confirming the completion of our Phase III trial of Lupuzor™, the Company is now at an exciting and pivotal phase of its development. We were approached by new institutions, introduced by Turner Pope Investments, keen to support ImmuPharma over the next period of growth. We are therefore delighted to be able to announce this Placing that includes both new and existing institutions to support our continued development. The proceeds of the Placing allow the Company to make investment into potential indications emanating from the Company's P140 platform, in addition to lupus. The Placing further strengthens the balance sheet and enhances ImmuPharma's position in ongoing and future negotiations with potential partners for Lupuzor™. We look forward to providing our shareholders with further updates regarding the Lupuzor™ Phase III trial with key data still on track to be announced before the end of Q1 2018." Details of the Placing The Placing was undertaken by Northland Capital Partners Limited, the Company's Broker and Turner Pope Investments (TPI) Ltd, who acted as Subscription Agent. The Placing Shares will rank pari passu with the existing Ordinary Shares and application has been made to the London Stock Exchange for admission of the Placing Shares to trading on AIM ("Admission"). The Placing is conditional, inter alia, on Admission, and dealings are expected to commence at 8.00am on 30 January 2018. Total Voting Rights Following Admission the Company's enlarged issued share capital will comprise 139,467,430 Ordinary Shares with voting rights. The figure of 139,467,430 Ordinary Shares may therefore be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules. This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 ("MAR"). In addition, market soundings (as defined in MAR) were taken in respect of the Placing with the result that certain persons became aware of inside information (as defined in MAR), as permitted by MAR. This inside information is set out in this Announcement. Therefore, those persons that received inside information in a market sounding are no longer in possession of such inside information relating to the Company and its securities. | hamhamham1 | |
24/1/2018 06:39 | Does anyone know the proportion of patients on the trial wanted to continue for the six month extension?Was it say the majority of the 200 ? | jp1962 | |
24/1/2018 06:34 | Oh well I stand corrected chalky, my apologies, it’s just there are a lot of multiple aliases appearing on this thread, usually to try and spread negative stuff to try and orchestrate a move lower, clearly you don’t fit into that category. GL with VELA, I have been in since mid 0.2p’s, samecwith BLU, that is my exposure to Blockchain stuff, it could take time to really take off but happy with progress so far. I’ll get my coat! 😊 | ny boy | |
24/1/2018 00:51 | NY Boy What do you mean a pattern developing !?? Ive only recently joined because only just started investing Saw this stock tipped in shares magazine in Dec and bought into it .. It caught my eye because my daughter has a very mild lupus so i looked into it further unfortunately i came in above the what the share price is now (although i did buy more on the dip at 1.50 ..Im in untill the results are published , im not bothered about the share price at the moment just how many shares i have :) as this is either going 2 ways Ive weighed up the risks and im prepared to take my chance as it seems from my very basic knowledge there are more positive than negative I look on this board to hopefully gain more confidence in my decision but so far i find it lacking Nothing on this board is going to stop me buying this share and seeing it through PS ive also bought into VELA after you recommended it, so lets just hope your share picking is better than poor judgement of new members on this board | chalky230 | |
23/1/2018 23:27 | It would be nice if you let other people have an opinion on what is going to happen with this share rather than trying to shut them down. Very childish. You are now going to look very silly if there is a placing. | btfd497 | |
23/1/2018 23:20 | Oh dear, a pattern developing chalky230 Member since: 09 Jan 2018 | ny boy |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions